NCT01236404View on ClinicalTrials.gov

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)

DRUG

Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)

Once weekly injections for up to four weeks

Trial Locations (3)

55114

Prism Research, Saint Paul

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Clinical Research Center, Inc., Renton

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY